The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Halozyme Therapeutics Inc. shares valued at $537,469 were sold by LaBarre Michael J. on Oct 15 ’24. At $53.75 per share, LaBarre Michael J. sold 10,000 shares. The insider’s holdings dropped to 173,756 shares worth approximately $9.29 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, LaBarre Michael J. sold 10,000 shares, netting a total of over 532,590 in proceeds. Following the sale of shares at $53.26 each, the insider now holds 173,756 shares.
Before that, MICHAEL LABARRE had added 10,000 shares to its account. In a trade valued at $532,592, the Officer bought Halozyme Therapeutics Inc. shares for $53.26 each.
As published in a research note from Wells Fargo on October 07, 2024, Halozyme Therapeutics Inc. [HALO] has been rated down from an Overweight to an Equal weight and the price target has been revised to $62 from $58. Analysts at JP Morgan downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in mid September. As of June 07, 2024, Piper Sandler has decreased its “an Overweight” rating to a “Neutral” for HALO. Earlier on February 29, 2024, TD Cowen initiated its rating. Their recommendation was “an Outperform” for HALO stock.
Analyzing HALO Stock Performance
During the last five days, there has been a surge of approximately 5.53%. Over the course of the year, Halozyme Therapeutics Inc. shares have jumped approximately 44.64%. Shares of the company reached a 52-week high of $65.53 on 08/29/24 and a 52-week low of $33.15 on 02/05/24. A 50-day SMA is recorded $58.59, while a 200-day SMA reached $46.89. Nevertheless, trading volume fell to 0.91 million shares from 0.8 million shares the previous day.
Support And Resistance Levels for Halozyme Therapeutics Inc. (HALO)
According to the 24-hour chart, there is a support level at 52.96, which, if violated, would cause prices to drop to 52.46. In the upper region, resistance lies at 53.83. The next price resistance is at 54.20. RSI (Relative Strength Index) is 40.72 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.52, which suggests the price will decrease in the coming days. Percent R is at 69.04%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Halozyme Therapeutics Inc. (HALO)?
On July 24, 2023, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $61.
